Quibim Announces New Board of Directors To Promote Growth And Strategic Expansion
The new Quibim Board of Directors is composed of six members.
As the medical device industry rapidly expands, so does the need for executive leadership. Recently, several top executives have made moves within the industry. Some have taken new positions at other companies, while others have started their own businesses. Here’s a look at who’s been making headlines lately.
The new Quibim Board of Directors is composed of six members.
Raymond W Cohen is an accredited public company director with more than 40 years of experience in the life sciences industry.
Prior to joining Inari, Dr. Vivien Bonazzi served as chief biomedical data scientist and managing director at Deloitte Consulting LLP.
“Carrie Lachance has been at the center of InfuSystem’s succession plan for the past several years, and she is the ideal person to succeed Rich DiIorio having spent the last decade plus working her way up through ever greater positions of responsibility within the Company,” said Scott Shuda, Chairman of the board of InfuSystem.
“Celine brings a wealth of experience in advancing radiopharmaceutical precision oncology treatments from early development through to regulatory approval. As she steps into the leadership of our medical team, her expertise will be instrumental in progressing our pipeline and delivering new treatment options for patients,” said Dr. Andrew Cavey, Chief Executive Officer of ITM.
Nuage Therapeutics applying its proprietary technology to advance a pipeline of novel agents targeting oncogenic transcription factors.